HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Mixing Food In Legislation Changing US FDA Cannabinoid Rules Could Choke Its Progress

Executive Summary

Making lawful the use of hemp cannabinoids in supplements and food is a step in the right direction, but including food may doom it, say industry stakeholders. As well, CRN CEO Steve Mister notes FDA has stated reservations about using cannabinoids in food.

You may also be interested in...



Cannabinoid NDI Notification Failures Thicken Regulatory Cloud Over US Market

Clarity needed to remove unlawful label for using hemp- and cannabis-derived ingredients in supplements and food available in US. Rejections of two CBD NDI notifications could sour other firms on complying with requirement for cannabinoids or other ingredients, says food and drug law attorney Kristi Wolff.

After US FDA Objects To CBD Safety As NDIs, Supplement Industry Responds, What Else Is New?

Rejection of two firms’ proposals for using hemp-derived CBD in supplement isn’t stirring US businesses selling CBD supplements to pull products from market. For one firm that filed an unsuccessful NDI notification for full-spectrum hemp extract CBD, FDA rejection was agenda item with numerous other business, regulatory and legislative developments in its latest quarter.

NDI Notifications For CBD ‘Excluded’ On Arrival But US FDA Still Explains Where Safety Evidence Fails

CFSAN Office of Dietary Supplement Programs tells Charlotte’s Web and Irwin Naturals that not providing sufficient evidence of a reasonable assumption of safety for an NDI's intended use wasn’t the only reason each notification was rejected.

Related Content

Topics

UsernamePublicRestriction

Register

RS151367

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel